Form 4: Sutro Biopharma Director Acquires Stock Options

Sutro Biopharma director Daniel H. Petree acquired 10,000 stock options with an exercise price of $26.09, vesting over time with full vesting by June 5, 2027.

Summary

• Daniel H. Petree, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options on June 5, 2026.
• The stock options have an exercise price of $26.09 per share.
• These options are subject to vesting, with 8.33% vesting monthly, starting July 5, 2026.
• The award will be fully vested and exercisable by June 5, 2027, or the date of the issuer's 2027 annual stockholders meeting, whichever comes first.
• Following this transaction, Petree beneficially owns 10,000 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a director's commitment and potential belief in future stock performance through the acquisition of options, but provides no new operational or financial information.

Positives

• Director acquisition of stock options signals confidence in the company's future prospects.
• The vesting schedule aligns with continued service, incentivizing long-term commitment.
• The exercise price of $26.09 suggests a valuation expectation for the stock.

Negatives

• The filing only details the acquisition of options, not the company's current financial performance or operational updates.
• The value of the options is contingent on future stock price performance.

Risks

• The vesting of options is contingent on the reporting person's provision of service to the issuer.
• The ultimate value of the options depends on the company's ability to achieve its strategic goals and improve its stock price.

Future Outlook

The vesting schedule of the stock options suggests an expectation of continued company operations and potential stock price appreciation through June 2027.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biopharmaceutical sector as a means to attract and retain executive talent and align their interests with shareholders, especially during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The grant of options to a director may be viewed positively as a sign of confidence, but it does not immediately impact share value. The ultimate impact depends on the company's performance and the stock price appreciation allowing the options to be exercised profitably.
• Employees: The vesting schedule for the director's options is separate from employee compensation, but the overall incentive structure can influence company culture and motivation.
• Management: The option grant aligns the director's financial interests with the long-term success of the company.

Next Steps

• Vesting of stock options on a monthly basis starting July 5, 2026.
• Full vesting of stock options by June 5, 2027, or the 2027 annual stockholders meeting.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, Securities Exchange Act